RecruitingNot ApplicableNCT06723626

Effects of Intravenous Metabolic Recovery Agent in Elderly Septic Patients on Prognosis and Microcirculation.

Clinical Study of the Effect of Intravenous Hydrocortisone Combined With Vitamin C and Vitamin B1 Infusion on Prognosis and Sublingual Microcirculation in Elderly Patients With Sepsis or Septic Shock.


Sponsor

Southeast University, China

Enrollment

40 participants

Start Date

Jul 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study intends to observe the effect of intravenous hydrocortisone combined with vitamin C and vitamin B1 infusion on the prognosis and sublingual microcirculation in patients with sepsis or septic shock through a prospective randomized controlled study method.


Eligibility

Min Age: 60 YearsMax Age: 85 Years

Inclusion Criteria4

  • Age ≥60 and ≤85 years old;
  • Diagnosis of sepsis or septic shock;
  • Clinical judgment for hydrocortisone treatment;
  • Signing Informed Consent.

Exclusion Criteria7

  • patients in palliative care;
  • uncontrolled malignancy with multiple metastases;
  • ineffective surgical intervention for the infectious agent;
  • estimated death within 24 hours;
  • glucocorticoids used in the last 7 days;
  • allergy to hydrocortisone, vitamin c or vitamin B1;
  • inability to measure sublingual microcirculation.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetabolic resuscitation agent

Intervention group will receive intravenous hydrocortisone (200mg every 24 hours), vitamin C (1.5g every 6 hours), and thiamine (200 mg every 12 hours).

DRUGHydrocortisone

Placebo group will receive intravenous hydrocortisone 200mg every 24 hours.


Locations(1)

Zhongda Hospital Southeast University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06723626


Related Trials